Streetbeat News

Earnings

CANO

Cano Health reported worse-than-expected Q2 financial results, withdrew its guidance, and announced it is pursuing a sale process. The company also expressed doubt over its ability to continue as a going concern, leading to a drop in its share price.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 12:20 pm

BNRG

Brenmiller Energy reported a H1 EPS of $(0.29), a slight decrease compared to $(0.28) YoY.

Portfolio Pulse from Happy Mohamed

August 11, 2023 | 12:15 pm

CATX

Perspective Therapeutics reported Q4 losses of $(0.04) per share, a 300% decrease YoY. The company's sales also decreased by 16.65% to $2.09 million compared to $2.50 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 12:13 pm

XBIO

Xenetic Biosciences reported a net loss of $1.1 million for Q2, with a cash balance of $10.7 million.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 12:13 pm

YETI

YETI Holdings reported better-than-expected Q2 2023 earnings and raised its FY23 guidance. Despite a 4% Y/Y sales drop to $402.56 million, adjusted EPS of 0.57 beat the street estimate of $0.47. The company raised its FY23 adjusted EPS outlook to $2.23-$2.32 and sales growth outlook to 4%-5%. Following the announcement, YETI shares jumped 17.3% and analysts from Canaccord Genuity and Baird increased their price targets on YETI.

Portfolio Pulse from Lisa Levin

August 11, 2023 | 12:13 pm

CYAN

Cyanotech (NASDAQ:CYAN) reported Q1 losses of $(0.22) per share, a 175% decrease YoY. Sales also decreased by 23.38% to $5.15 million compared to $6.72 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 12:12 pm

OCUP

Ocuphire Pharma reported Q2 losses of $(0.24) per share, missing the analyst consensus estimate of $(0.23) by 4.35 percent. However, the company's quarterly sales of $3.67 million beat the analyst consensus estimate of $2.42 million by 51.82 percent.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 12:12 pm

IRON

Disc Medicine (NASDAQ:IRON) reported Q2 losses of $(0.74) per share, beating the analyst consensus estimate of $(0.86) by 13.95 percent.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 12:10 pm

RAPT

RAPT Therapeutics reported Q2 losses of $(0.66) per share, a 6.45% decrease from the same period last year.

Portfolio Pulse from Happy Mohamed

August 11, 2023 | 12:09 pm

PALI

Palisade Bio (NASDAQ:PALI) reported Q2 losses of $(0.53) per share, missing the analyst consensus estimate of $(0.45) by 17.78%. This is a 91.17% increase over losses of $(6.00) per share from the same period last year. The company has a cash balance of $16.4M to fund operations through 2024.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 12:09 pm